Sonoma Pharmaceuticals (FRA:O8Z) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:O8Z Sonoma Pharmaceuticals Inc FRA:O8Z
34 GF Score
Price €2.72
GF Value €6.04
! 4 Warning Signs
View Full Analysis

What is Sonoma Pharmaceuticals Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:O8Z vs YCBD, CVSI, AKAN: Short Interest Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Sonoma Pharmaceuticals's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sonoma Pharmaceuticals Short Interest vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sonoma Pharmaceuticals's Short Interest distribution charts can be found below:

* The bar in red indicates where Sonoma Pharmaceuticals's Short Interest falls into.


FRA:O8Z
34GF Score
Sonoma Pharmaceuticals Inc FRA:O8Z
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Sonoma Pharmaceuticals (FRA:O8Z) Overvalued in 2026?

Based on GuruFocus' analysis, Sonoma Pharmaceuticals stock appears to be undervalued. The current stock price of €2.72 is trading 55% below its estimated GF Value™ of €6.04.

Key valuation signals for FRA:O8Z:

  • Short Interest:
  • GF Value™: €6.04 vs. price of €2.72 (55% below fair value)
  • GF Score™: 34/100 with 4 warning signs

No single metric tells the full story. See the FRA:O8Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sonoma Pharmaceuticals Business Description

Other Exchanges SNOA:USA
Address 5445 Conestoga Court, Suite 150, Boulder, CO, USA, 80301
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.
34GF Score

Get the complete analysis for FRA:O8Z

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.72
Price
€6.04
GF Value